VolitionRx Limited (VNRX) News
Track canonical SquawkNews coverage tagged to VNRX, VolitionRx Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
VNRX - VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
VNRX - VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
EQUITY | Sep 17, 2026, 01:18 PM UTC
L
VNRX - VolitionRx Participates in Launch of DETECSEPS Program in France
VNRX - VolitionRx Participates in Launch of DETECSEPS Program in France
NEWS | Sep 17, 2026, 12:17 PM UTC
L
VolitionRx pre-pays $422k of 2025 convertible note; $2.04M Lind note remains outstanding
VolitionRx prepaid approximately $422,000 to retire its 2025 senior secured convertible note, eliminating that instrument and reducing potential equity overhang.Key Highlights:Original SEC Filing: VOLITIONRX LTD [ VNRX ]
REGULATION | Sep 14, 2026, 09:15 PM UTC
L
VNRX: Strong IP, new products, and global partnerships drive licensing and clinical adoption in 2026
Recent milestones include a $5M milestone opportunity, new product launches, and expansion into non-sepsis disease areas. The company leverages a strong IP portfolio, asset-light model, and global partnerships, with mult
EQUITY | Sep 10, 2026, 12:35 PM UTC
L
VNRX - Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
VNRX - Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
EQUITY | Sep 10, 2026, 12:17 PM UTC
M
Lagoda-backed holder files Schedule 13D after 7.4% VolitionRx stake
Fatima Dickey, via Lagoda Investment Management, disclosed a 7.4% stake in VolitionRx. The holder switched from a passive Schedule 13G to an active Schedule 13D filed September 4, 2026.
EQUITY | Sep 04, 2026, 09:37 PM UTC
L
Volitionrx files preliminary prospectus for 10,006,360 common shares
Volitionrx filed a preliminary prospectus for 10,006,360 shares of common stock to be offered by a selling stockholder.
REGULATION | Aug 28, 2026, 08:33 PM UTC
L
VNRX - VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets - Click For Releas
VNRX - VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
EQUITY | Aug 26, 2026, 01:17 PM UTC
L
Volition announces clinical validation for Nu.Q NETs biomarker in sepsis
Volition (VNRX) said clinical validation of its Nu.Q NETs biomarker in sepsis has been announced.
EQUITY | Aug 26, 2026, 12:17 PM UTC
L
VolitionRx reports Q2 2026 results and provides business update
VolitionRx Limited announces its second quarter 2026 financial results and a business update for VNRX, with no additional figures provided in the feed.
EARNINGS | Aug 13, 2026, 08:10 PM UTC
L
VNRX - Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
VNRX - Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
EQUITY | Aug 12, 2026, 12:17 PM UTC
L
VNRX - VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
VNRX - VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
EARNINGS | Aug 11, 2026, 08:10 PM UTC
M
Volition Publishes Paper On Capture-Seq Liquid Biopsy
Volition publishes peer-reviewed paper on new liquid biopsy tech
EQUITY | Aug 05, 2026, 12:48 PM UTC
H
Volition Advances Nu.Q Platform
Volition advances platform towards commercialization
EQUITY | Jul 30, 2026, 12:18 PM UTC
L
VolitionRx registers to sell 3.31M shares of common stock for holders
VolitionRx registers to sell 3.31M shares of common stock for holders
EQUITY | Jul 10, 2026, 09:31 PM UTC